Sobre el VHIR
Al Vall d’Hebron Institut de Recerca (VHIR) promovem la recerca biomèdica, la innovació i la docència. Més de 1.800 persones busquen comprendre les malalties avui per millorar-ne el tractament demà.
Recerca
Treballem per entendre les malalties, saber com funcionen i crear millors tractaments per als pacients. Coneix els nostres grups i les seves línies de recerca.
Persones
Les persones són el centre del Vall d'Hebron Institut de Recerca (VHIR). Per això ens vinculem amb els principis de llibertat de recerca, igualtat de gènere i actitud professional que promou l’HRS4R.
Assaigs clínics
La nostra tasca no és només bàsica o translacional; som líders en recerca clínica. Entra per saber quins assaigs clínics estem duent a terme i perquè som referent mundial en aquest camp.
Progrés
Volem que la recerca que es fa al Vall d’Hebron Institut de Recerca (VHIR) sigui un motor de transformació. Com? Identificant noves vies i solucions per fomentar la salut i el benestar de les persones.
Core facilities
Oferim un suport especialitzat als investigadors tant interns com externs, des d’un servei concret fins a l’elaboració d’un projecte complet. Tot, amb una perspectiva de qualitat i agilitat de resposta.
Actualitat
Et donem una porta d’entrada per estar al dia de tot el que passa al Vall d’Hebron Institut de Recerca (VHIR), des de les últimes notícies fins a les activitats i iniciatives solidàries futures que estem organitzant.
Speaker: Dr. Julia Kzhyshkowska, Head of Dept. of Innate Immunity and Tolerance. Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University.
ÀBSTRACTCancer is one of the leading causes of death, reduced quality of life and disability worldwide. cancer-specific and patient-specific programming of innate immunity is needed for in the success in development of new anticancer therapies, for improving the efficiency of immunotherapeutic tools, and in the personification of conventional therapies needs to consider. Intratumoral TAMs and their precursors, resident macrophages and circulating monocytes, are principal regulators of tumor progression and therapy resistance. The lecture will elucidate the progress in the identification of in subpopulations of circulating monocytes and intratumoral TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical parameters of carcinogenesis and therapy resistance. The state-of-the-art will be presented in our knowledge on the tumor-supporting functions of TAMs at all stages of tumor progression and highlight biomarkers, recently identified by single-cell and spatial analytical methods, that discriminate between tumor-promoting and tumor-inhibiting TAMs, where both subtypes express a combination of prototype M1 and M2 genes. Novel mechanisms involved in the crosstalk between epigenetic, signalling, transcriptional and metabolic pathways in monocytes and TAMs will be addressed. The lecture will next focus on the molecular mechanisms that TAMs use to interfere with anticancer therapeutics, and will summarize and critically evaluate the most advanced data from the clinical trials, which are divided into 4 categories: inhibition of TAM survival and differentiation, inhibition of monocyte/TAM recruitment into tumors, functional reprogramming of TAMs, and genetic engineering of anti-tumor macrophages.
Host: Dr. Matilde LLeonart, Research group leader "Head and neck cancer: Biomedical Research in Tumor Stem Cells" Vall Hebron Institut de Recerca (VHIR)